Figure 6: In vivo delivery of miR-96 and miR-182 via targeted nanoparticles targets the primary tumour in an orthotopic breast cancer model.
From: Local microRNA delivery targets Palladin and prevents metastatic breast cancer
(a) Live imaging of BALB/c mice with 4T1 (expressing mCherry) breast tumours induced in the mammary fat pad and implanted with hydrogels embedded with targeted gold NPs carrying miR-96, miR-182 or scrambled (Ctrl) miRNAs with and without cisplatin. (b) Ex vivo fluorescent images of breast tumours to evaluate mCherry expression and NPs (FITC) accumulation. (c) Primary tumour volume following treatment. Quantitative PCR (qPCR) determination of (d) miR-96, (e) miR-182, and (f) Palladin mRNA expression levels in mice treated with hydrogels embedded with targeted gold NPs carrying miR-96, miR-182 or scrambled (Ctrl) miRNAs with and without cisplatin. (g) H&E and immuno-histochemistry for Palladin, Vinculin and Ki-67 of resected tumours from treated mice. All values are presented as mean±s.e.m. (n=5, Student’s t-test, *P<0.05, **P<0.01, ***P<0.005).
